Hyperkalemia
Advertisement
Patients with chronic kidney disease (CKD) who develop hyperkalemia are at risk for serious adverse outcomes.
Participants were randomized to placebo or SZC 5 grams once daily on nondialysis days.
During an average follow-up of 3.9 years, 12.4% of patients (n=220,339) experienced at least one hyperkalemic episode.
There were no statistically significant differences in the effect of oral potassium binder treatment at each timepoint.
There was a five-fold higher risk of hyperkalemia with use of a steroidal MRA plus an ACEi or ARB.
At 60 days, 48% of patients had a patiromer proportion of days covered >80%.
Examining efficacy and safety of sacubitril/valsartan for patients with CKD.
Medical costs in patients with hyperkalemia receiving SCZ therapy.
Effects of SZC plus RAAS Inhibitor therapy on short-term medical costs in hyperkalemia.
There are limited treatment options to reduce persistent cardiovascular and renal risk in patients with type 2 diabetes ...
Previous studies have examined the role of medical nutrition therapy (MNT) in progression of chronic kidney disease ...
There are few data available regarding the associations among individuals on chronic peritoneal dialysis between ...
Advertisement
